I am currently Professor of Public Heath in the Department of Public Health and Primary Care at Imperial College London as well as Honorary Consultant Cardiologist at the Imperial College NHS Trust. I received my medical education (MB ChB, 1991) at the University of Birmingham Medical School, my MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
My research interests have focused on the prevention of cardiovascular disease with a special interest in lipids and diabetes. I have investigated the early benefits of statin therapy, the advantages of more/less intensive glycaemic control, and the risks/benefits of aspirin therapy. These have influenced AHA/ACC and ESC guidelines. My work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. I continue to investigate the role of lipids, lipoproteins, diabetes, inflammation and thrombosis and coronary events. I have received research grants including from the British Heart Foundation, the Wellcome Trust, Pfizer, Amgen, Sanofi, MSD, and the European Atherosclerosis Society (EAS). Currently I lead the EAS Familial Hypercholesterolaemia (FH) Studies collaboration which is the first global registry for FH and now includes approximately sixty countries, and am the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.
I am a Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, I am also a member of the British Cardiovascular Society and European Atherosclerosis Society. I have been the national lead investigator and have served on the steering and executive committees for several major medical trials. I am currently involved in eight trials including PI of ORION 1 and BETONMACE.
I have published over 170 research articles in numerous journals including the NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal, which have been cited over 26,000 times.
et al., 2020, Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement, Lancet Diabetes and Endocrinology, Vol:8, ISSN:2213-8595, Pages:50-67
et al., 2019, Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies, Cardiovascular Diabetology, Vol:18, ISSN:1475-2840, Pages:1-10
et al., 2019, Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease, Atherosclerosis, Vol:290, ISSN:0021-9150, Pages:59-65
et al., 2019, Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial, American Heart Journal, Vol:217, ISSN:0002-8703, Pages:72-83
et al., 2019, Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial., The Lancet, Vol:394, ISSN:0140-6736, Pages:1169-1180